Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
11. September 2023 07:30 ET
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company formerly known as BiondVax Pharmaceuticals Ltd., announced today...
BiondVax Reports Second Quarter Financial Results and Provides Business Update
11. August 2023 09:00 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative...
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
01. August 2023 16:01 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative...
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.
11. Juli 2023 08:17 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, July 11, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce...
BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
05. Juni 2023 07:00 ET
|
BiondVax Pharmaceuticals Ltd.
Broad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential...
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
17. April 2023 16:25 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, April 17, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing...
BiondVax to Present at BIO-Europe Spring
16. März 2023 13:10 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing...
BiondVax Presenting at BIO CEO & Investor Conference
02. Februar 2023 14:15 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing...
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
23. Januar 2023 06:25 ET
|
BiondVax Pharmaceuticals Ltd.
COVID-19 illness was virtually prevented in hamsters administered BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2 Data further strengthens value proposition of BiondVax’s...
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study
06. Januar 2023 07:15 ET
|
BiondVax Pharmaceuticals Ltd.
Hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those treated...